⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4760230 | 0.86 | — | — | |
| SCHEMBL3314669 | 0.85 | — | — | |
| SCHEMBL11870215 | 0.77 | NOS1 (0.35) | — | |
| SCHEMBL11371793 | 0.73 | NOS1 (0.32) | — | |
| SCHEMBL11371796 | 0.73 | NOS1 (0.32) | — | |
| SCHEMBL432351 | 0.70 | — | — | |
| SCHEMBL815076 | 0.70 | NOS1 (0.37) | — | |
| SCHEMBL15536154 | 0.68 | — | — | |
| SCHEMBL9432594 | 0.67 | — | — | |
| SCHEMBL4984365 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3849968-A1 | 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) | Bristol-Myers Squibb Company (US) | 2021-07-21 | — | — | EP | claimed |
| WO-2020056072-A1 | 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-19 | — | — | WO | claimed |
| WO-2019190214-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF FIBROSIS | 크리스탈지노믹스(주) | 2019-10-03 | — | — | WO | claimed |
| EP-2118110-B1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-07-25 | — | — | EP | claimed |
| EP-2118110-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | Bristol-Myers Squibb Company (US) | 2009-11-18 | — | — | EP | claimed |
| US-7538102-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-26 | — | — | US | claimed |
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | claimed |
| WO-2008112851-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | claimed |
| WO-2003000682-A1 | (PYRIMIDYL)(PHENYL)SUBSTITUTED FUSED HETEROARYL P38 INHIBITING AND PKG KINASE INHIBITING COMPOUNDS | MERCK & CO., INC. (US) | 2003-01-03 | — | — | WO | claimed |
| US-4022781-A | ANTHELMINTIC AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1977-05-10 | — | — | US | claimed |
| EP-3849968-A1 | 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) | Bristol-Myers Squibb Company (US) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020056072-A1 | 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-19 | — | — | WO | disclosed |
| EP-2118110-B1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-2118110-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | Bristol-Myers Squibb Company (US) | 2009-11-18 | — | — | EP | disclosed |
| US-7538102-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-26 | — | — | US | disclosed |
| US-4020064-A | ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1977-04-26 | — | — | US | disclosed |
| US-3983106-A | ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-09-28 | — | — | US | disclosed |
| US-3969351-A | ANTHELMINTIC | E. R. SQUIBB & SONS, INC. (US) | 1976-07-13 | — | — | US | disclosed |
| US-3969351-A | ANTHELMINTIC | E. R. SQUIBB & SONS, INC. (US) | 1976-07-13 | — | — | US | disclosed |
| US-3969366-A | ANTIINFLAMMATORY | E. R. SQUIBB & SONS, INC. (US) | 1976-07-13 | — | — | US | disclosed |